Lawrence B. Cohen’s Moderna MRNA Stock Holding History

Lawrence B. Cohen’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,305	Closed	-$234K	–	79
2022 Q4	$234K	Buy	+1,305	New	+$213K	0.12%	84
2022 Q1	–	Sell	-1,025	Closed	-$260K	–	85
2021 Q4	$260K	Buy	+1,025	New	+$300K	0.1%	85

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lawrence B. Cohen's MRNA Position: Q1 2023 in Review

Lawrence B. Cohen sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,305 shares — an estimated $234K sold.

Lawrence B. Cohen first reported a position in MRNA in Q4 2021 and held it in 2 quarters. The position peaked at $260K in Q4 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Lawrence B. Cohen reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Lawrence B. Cohen sold 1,305 Moderna shares in Q1 2023, an estimated $234K.
Lawrence B. Cohen first reported a position in Moderna in Q4 2021 and held it in 2 quarters.
Lawrence B. Cohen's Moderna position peaked at $260K in Q4 2021.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Lawrence B. Cohen's 13F filing for Q1 2023, filed 11 May 2023.